NYSE:LH - Laboratory Corp. of America Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$148.76 +0.44 (+0.30 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$148.32
Today's Range$147.46 - $148.85
52-Week Range$119.38 - $190.35
Volume534,084 shs
Average Volume925,250 shs
Market Capitalization$15.01 billion
P/E Ratio13.50
Dividend YieldN/A
Beta1.13
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests, as well as with Baptist Health. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

Receive LH News and Ratings via Email

Sign-up to receive the latest news and ratings for LH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP50540R40
Phone336-229-1127

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.33 billion
Cash Flow$16.5657 per share
Book Value$69.09 per share

Profitability

Net Income$883.70 million

Miscellaneous

Employees60,000
Market Cap$15.01 billion
Next Earnings Date4/24/2019 (Estimated)
OptionableOptionable

Laboratory Corp. of America (NYSE:LH) Frequently Asked Questions

What is Laboratory Corp. of America's stock symbol?

Laboratory Corp. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."

How were Laboratory Corp. of America's earnings last quarter?

Laboratory Corp. of America Holdings (NYSE:LH) posted its quarterly earnings results on Thursday, February, 7th. The medical research company reported $2.52 EPS for the quarter, topping the Zacks' consensus estimate of $2.48 by $0.04. The medical research company had revenue of $2.79 billion for the quarter, compared to analysts' expectations of $2.78 billion. Laboratory Corp. of America had a return on equity of 17.05% and a net margin of 8.43%. The firm's revenue was up 1.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.45 EPS. View Laboratory Corp. of America's Earnings History.

When is Laboratory Corp. of America's next earnings date?

Laboratory Corp. of America is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for Laboratory Corp. of America.

What guidance has Laboratory Corp. of America issued on next quarter's earnings?

Laboratory Corp. of America updated its FY19 earnings guidance on Thursday, February, 7th. The company provided earnings per share (EPS) guidance of $11.00-11.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $11.22. The company issued revenue guidance of +0.5-2.5% to approximately $11.38-11.61 billion, compared to the consensus revenue estimate of $11.52 billion.Laboratory Corp. of America also updated its FY 2019 guidance to $11.00-11.40 EPS.

What price target have analysts set for LH?

17 analysts have issued 12 month price targets for Laboratory Corp. of America's shares. Their forecasts range from $155.00 to $202.00. On average, they expect Laboratory Corp. of America's share price to reach $178.2667 in the next twelve months. This suggests a possible upside of 19.8% from the stock's current price. View Analyst Price Targets for Laboratory Corp. of America.

What is the consensus analysts' recommendation for Laboratory Corp. of America?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Laboratory Corp. of America in the last year. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Laboratory Corp. of America.

What are Wall Street analysts saying about Laboratory Corp. of America stock?

Here are some recent quotes from research analysts about Laboratory Corp. of America stock:
  • 1. According to Zacks Investment Research, "LabCorp exited the fourth quarter on a promising note with better-than-expected earnings and revenues. Acquisitions and organic volume expansion positively contributed to LabCorp Diagnostics business in the last-reported quarter. This apart, Covance Drug Development has reported sturdy growth. This uptrend was primarily owing to strategic acquisitions and robust organic growth. On the flip side, in the quarter, the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act (PAMA) dented growth. According to the company, in Diagnostics, the fourth quarter was burdened with a number of non-operational items causing a 400 basis point decline in the operating margin. The company strongly expects 2019 to continue to witness similar hurdles. LabCorp has underperformed its industry in the past three months." (2/11/2019)
  • 2. Canaccord Genuity analysts commented, "We lower our estimates and PT from $162 to $155, which now uses a 13.8x multiple on our lower ’19 Adj. EPS of $11.30." (12/2/2018)

Has Laboratory Corp. of America been receiving favorable news coverage?

Headlines about LH stock have trended somewhat positive on Saturday, according to InfoTrie. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Laboratory Corp. of America earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Laboratory Corp. of America's key competitors?

What other stocks do shareholders of Laboratory Corp. of America own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Corp. of America investors own include CA (CA), BlackRock (BLK), Micron Technology (MU), Endologix (ELGX), Chipotle Mexican Grill (CMG), Amgen (AMGN), Allergan (AGN), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and Intel (INTC).

Who are Laboratory Corp. of America's key executives?

Laboratory Corp. of America's management team includes the folowing people:
  • Mr. David P. King, Chairman, CEO & Pres (Age 63)
  • Mr. Glenn A. Eisenberg, CFO & Exec. VP (Age 58)
  • Mr. F. Samuel Eberts III, Chief Legal Officer, Chief Compliance Officer, Sr. VP & Sec. (Age 59)
  • Mr. John D. Ratliff, Chief Exec. Officer of Covance Drug Devel. (Age 59)
  • Dr. Michelle Abelson, Laboratory Director of Operations

Who are Laboratory Corp. of America's major shareholders?

Laboratory Corp. of America's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.68%), Boston Partners (3.24%), Nordea Investment Management AB (2.10%), Amundi Pioneer Asset Management Inc. (1.95%), Dimensional Fund Advisors LP (1.45%) and Geode Capital Management LLC (1.40%). Company insiders that own Laboratory Corp. of America stock include Adam H Schechter, David P King, Dwight Gary Gilliland, Edward T Dodson, F Samuel Eberts III, Glenn A Eisenberg, Jean-Luc Belingard, Kerrii B Anderson, Lance Berberian, Lisa J Uthgenannt, M Huff Gary, R Sanders Williams and Robert E Mittelstaedt Jr. View Institutional Ownership Trends for Laboratory Corp. of America.

Which institutional investors are selling Laboratory Corp. of America stock?

LH stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Iridian Asset Management LLC CT, Jennison Associates LLC, Amundi Pioneer Asset Management Inc., Rothschild & Co. Asset Management US Inc., Bessemer Group Inc., Principal Financial Group Inc. and Retirement Systems of Alabama. Company insiders that have sold Laboratory Corp. of America company stock in the last year include David P King, Edward T Dodson, Glenn A Eisenberg, Kerrii B Anderson, Lisa J Uthgenannt, M Huff Gary and R Sanders Williams. View Insider Buying and Selling for Laboratory Corp. of America.

Which institutional investors are buying Laboratory Corp. of America stock?

LH stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Brandes Investment Partners LP, State of New Jersey Common Pension Fund D, Squarepoint Ops LLC, Nordea Investment Management AB, CI Investments Inc., Two Sigma Advisers LP and Acadian Asset Management LLC. View Insider Buying and Selling for Laboratory Corp. of America.

How do I buy shares of Laboratory Corp. of America?

Shares of LH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Laboratory Corp. of America's stock price today?

One share of LH stock can currently be purchased for approximately $148.76.

How big of a company is Laboratory Corp. of America?

Laboratory Corp. of America has a market capitalization of $15.01 billion and generates $11.33 billion in revenue each year. The medical research company earns $883.70 million in net income (profit) each year or $11.02 on an earnings per share basis. Laboratory Corp. of America employs 60,000 workers across the globe.

What is Laboratory Corp. of America's official website?

The official website for Laboratory Corp. of America is http://www.labcorp.com.

How can I contact Laboratory Corp. of America?

Laboratory Corp. of America's mailing address is 358 South Main Street, BURLINGTON NC, 27215. The medical research company can be reached via phone at 336-229-1127 or via email at [email protected]


MarketBeat Community Rating for Laboratory Corp. of America (NYSE LH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  442 (Vote Outperform)
Underperform Votes:  476 (Vote Underperform)
Total Votes:  918
MarketBeat's community ratings are surveys of what our community members think about Laboratory Corp. of America and other stocks. Vote "Outperform" if you believe LH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel